정맥주사용 면역글로불린 세계 시장 규모는 2023년 117억 6,000만 달러에 달할 것으로 예상되며, 2029년까지 예측 기간 동안 연평균 7.01%의 견조한 성장세를 보일 것으로 예상됩니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2025-2029년 |
| 시장 규모 : 2023년 | 117억 6,000만 달러 |
| 시장 규모 : 2029년 | 175억 9,000만 달러 |
| CAGR : 2024-2029년 | 7.01% |
| 급성장 부문 | 원발성 면역결핍증 |
| 최대 시장 | 북미 |
세계 정맥주사용 면역글로불린(IVIG) 시장은 최근 몇 년동안 면역 결핍 질환의 유병률 증가, 노인 인구 증가, 생명 공학 및 의료 인프라의 발전 등의 요인으로 인해 크게 성장하고 발전해 왔습니다. IVIG 시장은 글리벡, CSL 베링, 다케다제약, 옥타파마 등 여러 주요 기업들이 시장을 지배하고 있으며, 치열한 경쟁 환경으로 인해 IVIG는 다양한 자가면역질환과 염증성 질환을 치료하기 위해 정맥으로 투여되고 있습니다. 경쟁 환경이 특징입니다. 이들 기업은 제품 포트폴리오를 확장하고, 제조 공정을 강화하며, IVIG 제품의 효능과 안전성 프로파일을 개선하기 위해 R&D 활동에 지속적으로 투자하고 있습니다. 또한 전략적 제휴, 합병 및 인수는 시장 진출기업들이 시장에서의 입지를 강화하고 경쟁 우위를 확보하기 위해 채택하는 일반적인 전략입니다.
지리적으로 볼 때, 북미가 세계 IVIG 시장을 독점하고 있습니다. 이는 높은 면역 결핍 질환 유병률, 잘 정비된 의료 인프라, 유리한 상환 정책 등의 요인에 기인합니다. 그러나 아시아태평양은 의료비 지출 증가, 면역글로불린 치료에 대한 인식 증가, 자가면역질환 및 염증성 질환의 유병률 증가로 인해 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다. 또한, 고급 의료 서비스 및 치료에 대한 접근성을 개선하기 위해 정부 및 의료 기관에서 시행하고 있는 이니셔티브는 이 지역 시장 성장을 더욱 촉진할 것으로 예상됩니다. 긍정적인 성장 전망에도 불구하고 IVIG 시장은 제품 승인에 대한 엄격한 규제 요건, IVIG 치료에 따른 높은 비용, 알레르기 반응, 혈전증, 감염 전파 등 부작용의 잠재적 위험과 같은 특정 과제에 직면해 있습니다. 또한, 혈장 기증자가 한정되어 있고 혈장 채취율이 변동하기 때문에 제조업체는 시장 수요를 충족하는 IVIG 제품의 안정적이고 지속적인 공급을 보장하는 데 있어 추가적인 어려움을 겪고 있습니다. 그러나 혈장 분획 기술의 지속적인 발전, 엄격한 품질 관리 조치의 시행, IVIG 치료의 안전성과 효능을 향상시키기 위한 연구 개발 활동에 대한 투자 증가는 이러한 과제를 완화하고 향후 몇 년동안 시장 성장을 가속할 것으로 예상됩니다.
면역결핍증 유병률 증가
자가면역질환 및 신경질환에 대한 적용 확대
생명공학 및 제조 공정의 발전
규제상의 장애물
IVIG 치료의 높은 비용
공급망 취약성
IVIG 제조 기술의 발전
의료비 지출 증가 및 상환 지원
Global Intravenous Immunoglobulin Market was valued at USD 11.76 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.01% through 2029.
| Market Overview | |
|---|---|
| Forecast Period | 2025-2029 |
| Market Size 2023 | USD 11.76 Billion |
| Market Size 2029 | USD 17.59 Billion |
| CAGR 2024-2029 | 7. 01% |
| Fastest Growing Segment | Primary Immunodeficiency Diseases |
| Largest Market | North America |
The global intravenous immunoglobulin (IVIG) market has witnessed substantial growth and evolution in recent years, driven by factors such as increasing prevalence of immunodeficiency disorders, rising geriatric population, and advancements in biotechnology and healthcare infrastructure. IVIG, a blood product derived from the plasma of healthy donors, contains a high concentration of antibodies and is administered intravenously to treat various autoimmune and inflammatory diseases, including primary immunodeficiency disorders, autoimmune neuropathies, and certain infectious diseases. The market for IVIG is characterized by a competitive landscape with several key players dominating the industry, including Grifols, CSL Behring, Takeda Pharmaceutical Company Limited, and Octapharma AG, among others. These companies are continuously investing in research and development activities to expand their product portfolios, enhance manufacturing processes, and improve the efficacy and safety profiles of their IVIG products. Additionally, strategic collaborations, mergers, and acquisitions are prevalent strategies adopted by market players to strengthen their market presence and gain a competitive edge.
Geographically, North America dominates the global IVIG market, attributed to factors such as high prevalence of immunodeficiency disorders, well-established healthcare infrastructure, and favorable reimbursement policies. However, the Asia Pacific region is expected to witness significant growth during the forecast period, driven by increasing healthcare expenditure, growing awareness about immunoglobulin therapies, and rising prevalence of autoimmune and inflammatory diseases. Moreover, initiatives undertaken by governments and healthcare organizations to improve access to advanced healthcare services and treatments are expected to further fuel market growth in the region. Despite the positive growth outlook, the IVIG market faces certain challenges, including stringent regulatory requirements for product approval, high costs associated with IVIG therapy, and potential risks of adverse reactions such as allergic reactions, thrombotic events, and transmission of infectious agents. Moreover, limited availability of plasma donors and fluctuations in plasma collection rates pose additional challenges for manufacturers in ensuring a stable and sustainable supply of IVIG products to meet market demand. However, ongoing advancements in plasma fractionation technologies, implementation of stringent quality control measures, and increasing investment in research and development activities aimed at improving the safety and efficacy of IVIG therapies are expected to mitigate these challenges and drive market growth in the coming years.
Key Market Drivers
Growing Prevalence of Immunodeficiency Disorders
The growing prevalence of immunodeficiency disorders is a significant factor driving the expansion of the global intravenous immunoglobulin (IVIG) market. Immunodeficiency disorders encompass a range of conditions characterized by impaired immune function, leaving individuals vulnerable to recurrent infections and other complications. Primary immunodeficiency diseases (PIDs), such as agammaglobulinemia, common variable immunodeficiency (CVID), and specific antibody deficiency (SAD), are among the most commonly diagnosed disorders in this category. One of the primary reasons behind the increasing prevalence of immunodeficiency disorders is improved diagnostic capabilities and awareness among healthcare professionals. Advancements in medical technology and screening methods have enabled more accurate and timely diagnosis of these conditions, leading to a higher reported prevalence. Growing awareness campaigns and educational initiatives aimed at healthcare providers and the general public have contributed to early detection and intervention, further driving up the number of diagnosed cases.
The rise in immunodeficiency disorders is also attributed to factors such as genetic predisposition, environmental factors, and lifestyle changes. Genetic mutations or defects in the immune system can predispose individuals to immunodeficiency disorders, while environmental factors such as pollution, exposure to toxins, and infectious agents may exacerbate immune dysfunction. Moreover, lifestyle factors such as stress, poor nutrition, and sedentary behavior can compromise immune function, increasing susceptibility to infections and immune-related disorders.
The increasing prevalence of immunodeficiency disorders has led to a corresponding rise in the demand for IVIG therapy. IVIG products, derived from plasma donors, contain a concentrated mixture of antibodies that can help bolster the immune response in individuals with immunodeficiency disorders. By supplying exogenous antibodies, IVIG therapy compensates for the defective or deficient immune system, reducing the frequency and severity of infections and improving overall quality of life for patients.
Healthcare providers are increasingly turning to IVIG therapy as a standard treatment option for managing immunodeficiency disorders. This growing demand for IVIG products is fueling market growth, prompting manufacturers to expand production capacities, improve product quality, and invest in research and development to meet the needs of patients worldwide. Advancements in biotechnology and manufacturing processes are driving efficiency gains in IVIG production, enhancing product safety, and expanding market access, further bolstering the growth of the global IVIG market.
Expanding Applications in Autoimmune and Neurological Disorders
The expanding applications of intravenous immunoglobulin (IVIG) in autoimmune and neurological disorders are playing a pivotal role in driving the growth of the global IVIG market. IVIG therapy, traditionally used to treat immunodeficiency disorders, has increasingly found utility in managing a wide array of autoimmune conditions and neurological diseases. Autoimmune disorders, characterized by the body's immune system attacking its own tissues and organs, encompass a diverse range of conditions such as immune thrombocytopenic purpura (ITP), Guillain-Barre syndrome (GBS), myasthenia gravis (MG), and systemic lupus erythematosus (SLE), among others. IVIG therapy has emerged as an effective treatment modality for these disorders due to its immunomodulatory properties. IVIG contains a high concentration of antibodies that can modulate immune responses, suppress inflammatory pathways, and promote immune tolerance, thereby mitigating autoimmune reactions and reducing disease activity. As a result, healthcare providers are increasingly prescribing IVIG therapy as a first-line or adjunctive treatment option for managing autoimmune disorders, driving up the demand for IVIG products.
In addition to autoimmune disorders, IVIG therapy is also gaining traction in the field of neurology for the treatment of various neurological conditions. Chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and stiff person syndrome (SPS) are among the neurological disorders that have shown positive responses to IVIG treatment. IVIG exerts neuroprotective effects by modulating immune-mediated neuroinflammation, promoting nerve regeneration, and restoring neuromuscular function. In CIDP, for example, IVIG therapy has been shown to improve muscle strength, reduce disability, and prevent disease relapse, leading to its widespread adoption as a standard treatment option.
The expanding applications of IVIG in autoimmune and neurological disorders are driving market growth by increasing the demand for IVIG products across diverse therapeutic indications. As research continues to uncover new therapeutic targets and treatment strategies, the potential applications of IVIG therapy are expected to expand further, creating opportunities for market expansion and innovation. Moreover, advancements in biotechnology and manufacturing processes are enhancing the efficacy, safety, and accessibility of IVIG products, further fueling market growth and meeting the evolving needs of patients with autoimmune and neurological conditions.
Advancements in Biotechnology and Manufacturing Processes
Advancements in biotechnology and manufacturing processes are significant drivers behind the growth of the global intravenous immunoglobulin (IVIG) market. These advancements have led to improvements in the quality, safety, and efficacy of IVIG products, thereby expanding their utilization across various therapeutic applications. One of the key advancements in biotechnology is the refinement of plasma fractionation techniques. Plasma, the raw material used in IVIG production, undergoes a complex fractionation process to isolate and purify immunoglobulins. Innovations in fractionation technology have enabled manufacturers to produce IVIG products with higher purity levels and reduced levels of contaminants. This has resulted in safer and more effective IVIG therapies, minimizing the risk of adverse reactions and ensuring better patient outcomes.
Advancements in viral inactivation and pathogen reduction techniques have enhanced the safety profile of IVIG products. Viral inactivation methods such as solvent-detergent treatment, pasteurization, and nanofiltration are employed during the manufacturing process to eliminate potential pathogens and infectious agents from the plasma-derived products. These advancements have significantly reduced the risk of transfusion-transmitted infections, making IVIG therapy safer for patients with compromised immune systems.
Improvements in formulation technologies have facilitated the development of stabilized liquid IVIG formulations. Traditionally, IVIG products were available in lyophilized (freeze-dried) form, requiring reconstitution before administration. However, liquid IVIG formulations offer several advantages, including convenience in storage and administration, reduced preparation time, and lower risk of medication errors. These advancements in formulation technology have improved patient compliance and healthcare provider convenience, driving the adoption of IVIG therapy across various clinical settings. Advancements in manufacturing processes have enabled scalability and increased production capacities, ensuring a stable and sustainable supply of IVIG products to meet growing market demand. Automation and optimization of manufacturing workflows have led to cost efficiencies and reduced production timelines, enabling manufacturers to scale up production and meet the needs of patients worldwide.
Key Market Challenges
Regulatory Hurdles
One of the primary challenges facing the IVIG market is the stringent regulatory requirements for product approval and manufacturing. Regulatory agencies impose rigorous standards for the production, testing, and distribution of IVIG products to ensure their safety, efficacy, and quality. Compliance with these regulations involves substantial investments in infrastructure, quality control measures, and documentation, which can significantly impact manufacturing costs and timelines. Differences in regulatory requirements across regions and countries can create barriers to market entry and expansion, further complicating the regulatory landscape for IVIG manufacturers.
High Cost of IVIG Therapy
The high cost of IVIG therapy poses a significant barrier to patient access and market growth. IVIG products are expensive to manufacture due to the complex fractionation process involved in plasma-derived products, as well as the stringent quality control measures required to ensure product safety and efficacy. As a result, IVIG therapies are associated with high treatment costs, placing financial strain on patients, healthcare systems, and payers. Limited reimbursement coverage for IVIG therapy in some regions further exacerbates the affordability issue, restricting patient access to treatment and constraining market demand.
Supply Chain Vulnerabilities
The global IVIG market relies heavily on a stable and sustainable supply of plasma, the raw material used in IVIG production. Plasma collection involves a complex and highly regulated process, which can be susceptible to disruptions due to factors such as donor availability, seasonal fluctuations, and regulatory changes. Moreover, the consolidation of plasma collection centers and the dependence on a limited number of plasma suppliers can increase the vulnerability of the IVIG supply chain to supply shortages and disruptions. These supply chain vulnerabilities pose risks to market stability and continuity of care for patients dependent on IVIG therapy.
Key Market Trends
Technological Advancements in IVIG Production
Technological advancements in IVIG production are playing a pivotal role in boosting the global intravenous immunoglobulin (IVIG) market. IVIG, derived from plasma donors, is a critical therapeutic agent used in the treatment of various autoimmune, immunodeficiency, and neurological disorders. Advancements in IVIG production processes have led to improved efficiency, quality, and safety of IVIG products, thereby expanding their availability and utilization across diverse therapeutic indications. One of the key technological advancements in IVIG production is the refinement of plasma fractionation techniques. Plasma, the raw material used in IVIG production, undergoes a complex fractionation process to isolate and purify immunoglobulins. Innovations in fractionation technology have enabled manufacturers to produce IVIG products with higher purity levels and reduced levels of contaminants. This has resulted in safer and more effective IVIG therapies, minimizing the risk of adverse reactions and ensuring better patient outcomes.
Advancements in viral inactivation methods have further enhanced the safety profile of IVIG products. Viral inactivation techniques such as solvent-detergent treatment, pasteurization, and nanofiltration are employed during the manufacturing process to eliminate potential pathogens and infectious agents from the plasma-derived products. These advancements have significantly reduced the risk of transfusion-transmitted infections, making IVIG therapy safer for patients with compromised immune systems. Improvements in formulation technologies have facilitated the development of stabilized liquid IVIG formulations. Traditionally, IVIG products were available in lyophilized (freeze-dried) form, requiring reconstitution before administration. However, liquid IVIG formulations offer several advantages, including convenience in storage and administration, reduced preparation time, and lower risk of medication errors. These advancements in formulation technology have improved patient compliance and healthcare provider convenience, driving the adoption of IVIG therapy across various clinical settings.
Advancements in manufacturing processes have enabled scalability and increased production capacities, ensuring a stable and sustainable supply of IVIG products to meet growing market demand. Automation and optimization of manufacturing workflows have led to cost efficiencies and reduced production timelines, enabling manufacturers to scale up production and meet the needs of patients worldwide.
Rising Healthcare Expenditure and Reimbursement Support
Rising healthcare expenditure and reimbursement support are key factors boosting the global intravenous immunoglobulin (IVIG) market. IVIG, derived from plasma donors, is a crucial therapeutic agent used in the treatment of various autoimmune, immunodeficiency, and neurological disorders. The increasing healthcare expenditure and favorable reimbursement policies create a conducive environment for market growth in the IVIG segment, ensuring affordability and accessibility for patients. As healthcare expenditure continues to rise globally, governments and healthcare organizations are prioritizing investments in healthcare infrastructure and expanding access to advanced medical treatments. IVIG therapy, being a life-saving treatment for many patients with immunodeficiency disorders and other conditions requiring IVIG, is among the areas benefiting from increased healthcare spending. Governments are allocating substantial funds to support research and development initiatives, enhance healthcare delivery systems, and improve patient access to innovative therapies like IVIG.
Favorable reimbursement policies play a critical role in driving market adoption and uptake of IVIG therapy. Reimbursement policies that provide coverage for IVIG treatments ensure affordability for patients, reducing financial barriers to access. Health insurance companies and government healthcare programs often provide reimbursement for IVIG therapy, either partially or in full, depending on the specific indication and healthcare system regulations. This reimbursement support incentivizes healthcare providers to prescribe IVIG therapy and encourages patients to seek treatment, thereby driving market demand.
Collaborations between manufacturers and healthcare providers are also contributing to the optimization of reimbursement processes and patient access to IVIG therapy. Manufacturers work closely with healthcare providers, payers, and patient advocacy groups to streamline reimbursement procedures, address reimbursement challenges, and optimize patient access to IVIG products. By improving reimbursement processes and increasing awareness about reimbursement coverage options, stakeholders in the IVIG market are enhancing patient access to treatment and driving market growth.
Segmental Insights
Type Insights
Based on the type, In the Intravenous Immunoglobulin (IVIG) market, Immunoglobulin G (IgG) dominates due to its extensive therapeutic applications and proven efficacy. IgG constitutes the majority of immunoglobulins in plasma, making it crucial for immune response regulation and pathogen neutralization. Its wide-ranging use in treating immunodeficiency disorders, autoimmune diseases, and acute infections underpins its market leadership. IgG's established safety profile, coupled with ongoing advancements in purification and production technologies, enhances its therapeutic potential and accessibility. As a result, IgG remains the cornerstone of IVIG therapies, driving its dominance in the market.
Regional Insights
North America emerged as the dominant region in the global intravenous immunoglobulin (IVIG) market, commanding the largest market share. This dominance can be attributed to North America's well-established healthcare infrastructure, which comprises advanced medical facilities and a robust regulatory framework. The region is home to numerous prominent pharmaceutical and biotechnology companies specializing in IVIG production, research, and development. Leveraging the region's favorable regulatory environment and access to cutting-edge technology, these companies have developed high-quality IVIG products that meet stringent safety and efficacy standards. Additionally, North America benefits from extensive research and clinical trials conducted in collaboration with leading academic institutions and healthcare organizations, further solidifying its position as a key player in the global IVIG market.
Bio Products Laboratory Ltd.
Biotest AG
China Biologic Products Holdings Inc.
CSL Behring
Grifols SA
Kedrion SpA
Shanghai RAAS Blood Products Co. Ltd
Octapharma AG
Takeda Pharmaceutical Company Limited
Baxter International Inc
In this report, the Global Intravenous Immunoglobulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Immunoglobulin Market.
Global Intravenous Immunoglobulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Detailed analysis and profiling of additional market players (up to five).